Illness Risk Following Rapid Versus Gradual Discontinuation of Antidepressants
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Rapid discontinuation of some psychotropic medications is followed by discontinuation symptoms as well as an increased risk of early illness recurrence. Recurrence occurs earlier after rapid than after gradual discontinuation with lithium and antipsychotics. The authors compared illness recurrence after rapid versus gradual discontinuation of antidepressants. METHOD: The authors compared 398 patients with a DSM-IV diagnosis of recurrent major depressive disorder (N=224), panic disorder (N=75), bipolar II disorder (N=62), or bipolar I disorder (N=37). Two-thirds were women, the mean age was 42 years, and patients were treated with antidepressants for a mean of 8.5 months. Antidepressants were discontinued clinically, either rapidly (over 1-7 days; N=188) or gradually (over 14 days or more; N=210), with a mean follow-up duration of 2.8 years; patients who were ill at discontinuation were excluded from the analysis. The authors compared latency to first new illness episodes using survival analysis and Cox multivariate modeling. RESULTS: The latency to first illness with rapid discontinuation was 0.4 times that with gradual discontinuation, and the latency after rapid discontinuation was one-fourth the estimated average previous interepisode interval in the same patients. The effect was similar across antidepressant classes and across years; the pace of discontinuation had less effect with drugs of prolonged half-life. The effect also varied by diagnosis (bipolar I > or = panic > bipolar II > or = major depressive disorder) but not by episodes per year, duration of index illness, use of concomitant treatment, or antidepressant dose or duration. CONCLUSIONS: The recurrence risk for depression or panic was much shorter after rapid than after gradual discontinuation of antidepressants. These findings have implications for both clinical management and the design and interpretation of clinical trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“One study found that tapering over 4 weeks was not feasible, with most (60%) patients tapering their medications over 4 months 41 .”
From Tapering of SSRI treatment to mitigate withdrawal symptoms (2019) · cites this paper as [41]
In the citing paper
“Indeed, even reductions from 2•5 mg (a quarter of the smallest available tablet) to 0mg will produce a reduction in SERT inhibition of 42•9%, and reduction from 1•25mg (an eighth of a tablet) to 0mg will produce a 28% reduction (larger than the change from 40mg to 5mg (27•3%)), perhaps accounting for the lack of success of previous tapering regimes 41,42 , and particularly for the difficulties”
From Tapering of SSRI treatment to mitigate withdrawal symptoms (2019) · cites this paper as [41]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Cohen, L. S. (2006) · JAMA · doi:10.1001/jama.295.5.499 · Cited by 1,031
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945
THE TREATMENT OF DEPRESSIVE STATES WITH G 22355 (IMIPRAMINE HYDROCHLORIDE)
KUHN, R. (1958) · American Journal of Psychiatry · doi:10.1176/ajp.115.5.459 · Cited by 615
Viguera, A. C., Nonacs, R., Cohen, L. S., Tondo, L., Murray, A., & Baldessarini, R. J. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.2.179 · Cited by 488
Self-citationRisk of Recurrence Following Discontinuation of Lithium Treatment in Bipolar Disorder
Suppes, T. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810360046007 · Cited by 392
Study of Compulsive Buying in Depressed Patients
Lejoyeux, M., Tassain, V., Solomon, J., & AdAs, J. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0406 · Cited by 271
Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment
Viguera, A. C. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830130055011 · Cited by 246
Outcome After Rapid vs Gradual Discontinuation of Lithium Treatment in Bipolar Disorders
Faedda, G. L. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820180046005 · Cited by 239
Antidepressant Discontinuation Syndromes: Clinical Relevance, Prevention and Management
Haddad, P. M. (2001) · Drug Safety · doi:10.2165/00002018-200124030-00003 · Cited by 214
Mojtabai, R., & Olfson, M. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0704 · Cited by 185
Suicidal risks among 2826 Sardinian major affective disorder patients
Tondo, L., Lepri, B., & Baldessarini, R. J. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2007.01066.x · Cited by 177
Self-citationAntidepressant discontinuation syndromes
Haddad, P. M., Anderson, I., & Rosenbaum, J. (2004) · Adverse Syndromes and Psychiatric Drugs · doi:10.1093/med/9780198527480.003.0010 · Cited by 160
Antidepressant withdrawal phenomena.
Dilsaver, S. C., & Greden, J. F. (1984) · PubMed · Cited by 157
Discontinuing lithium maintenance treatment in bipolar disorders: risks and implications
Baldessarini, R. J., Tondo, L., & Viguera, A. C. (1999) · Bipolar Disorders · doi:10.1034/j.1399-5618.1999.10106.x · Cited by 153
Discontinuing antidepressant treatment in major depression.
Viguera, A. C., Baldessarini, R. J., & Friedberg, J. (1998) · Harvard Review of Psychiatry · doi:10.3109/10673229809003578 · Cited by 145
Valuck, R. J., Libby, A. M., Orton, H. D., Morrato, E. H., Allen, R., & Baldessarini, R. J. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07010007 · Cited by 137
Tondo, L., Baldessarini, R. J., & Floris, G. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.41.s184 · Cited by 132
Self-citationHypomania and mania after withdrawal of tricyclic antidepressants
(1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.1.87 · Cited by 95
Schatzberg, A. F., Blier, P., Delgado, P. L., Fava, M., Haddad, P. M., & Shelton, R. C. (2006) · PubMed · Cited by 94
Hindmarch, I., Kimber, S., & Cockle, S. M. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015060-00001 · Cited by 84
EEG lateral asymmetries in psychiatric disorders
Serafetinides, E. A. (1984) · Biological Psychology · doi:10.1016/0301-0511(84)90040-1 · Cited by 78
TOFRANIL‐TREATMENT OF ENDOGENOUS DEPRESSIONS
Andersen, H., & Kristiansen, E. S. (1959) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1959.tb07529.x · Cited by 73
van Geffen, E. C. G., Hugtenburg, J. G., Heerdink, E. R., van Hulten, R. P., & Egberts, A. C. G. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0921-x · Cited by 72
Possible Biological Mechanisms of the Serotonin Reuptake Inhibitor Discontinuation Syndrome
Schatzberg, A. F., Haddad, P. M., Kaplan, E. M., Lejoyeux, M., Rosenbaum, J. F., Young, A. H., & Zajecka, J. (1997) · The Journal of Clinical Psychiatry · Cited by 69
Long-term treatment of recurrent and chronic depression.
Keller, M. B. (2001) · PubMed · Cited by 66
Gelenberg, A. J. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0101 · Cited by 58
The interaction of drug- and psychotherapy in the long-term treatment of depression
Kupfer, D. J., & Frank, E. (2001) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00357-8 · Cited by 57
Himei, A., & Okamura, T. (2006) · CNS Drugs · doi:10.2165/00023210-200620080-00005 · Cited by 56
Antidepressant-Withdrawal Mania: A Critical Review and Synthesis of the Literature
Andrade, C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0716 · Cited by 49
Gardarsdottir, H., Egberts, T. C., Stolker, J. J., & Heerdink, E. R. (2009) · American Journal of Epidemiology · doi:10.1093/aje/kwp142 · Cited by 47
Baldessarini, R. J., Suppes, T., & Tondo, L. (1996) · American Journal of Therapeutics · doi:10.1097/00045391-199607000-00004 · Cited by 27
Tint, A., Haddad, P. M., & Anderson, I. M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107087488 · Cited by 13
Lithium in neuropsychiatry: results from brain imaging studies
Monkul, E. S., & Soares, J. C. (2013) · CRC Press eBooks · doi:10.3109/9780203007051-43 · Cited by 9
Long-term outcome of anxiety disorders: a review of double-blind studies
THUILE, J., EVEN, C., & Rouillon, F. (2008) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32831a726d · Cited by 6
Research works printed but not linked: 6
- National Center for Health Statistics, 2007, Health United States–2007, 333
- Schatzberg AR, 1997, J Clin Psychiatry, 58, 23
- Duenwald M, 2004, New York Times, D1
- Schatzberg AF, 2006, J Clin Psychiatry, 67, 27
- 10.1177/0269881107081550 · doi:10.1177/0269881107081550 · Paper page
- Baldessarini RJ : Drug therapy of depression and anxiety disorders, in Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th ed . Edited by , Brunton LL , Lazo JS , Parker KL. New York, McGraw-Hill, 2005, pp 429–459
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
“5 times more quickly when discontinuation was rapid versus gradual (355).”
BackgroundCleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
“The optimum rate to taper drug dose is unknown, with opinions varying from a few weeks to a year (Greden, 1993); however, a case-note review of nearly 400 patients followed-up for an average of nearly 3 years suggest that the risk of relapse into a new episode of illness is higher following rapid (1–7 day) versus grad…”
BackgroundBaldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Self-citationTapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280
Episodes of Mood Disorders in 2,252 Pregnancies and Postpartum Periods
Viguera, A. C., Tondo, L., Koukopoulos, A. E., Reginaldi, D., Lepri, B., & Baldessarini, R. J. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11010148 · Cited by 279
Metadata
- Authors
- Baldessarini, R. J., Tondo, L., Ghiani, C., & Lepri, B.
- Affiliations
- Harvard University (US)
- Venue
- American Journal of Psychiatry
- Published
- 2010-08-01
- Volume
- 167
- Issue
- 8
- Pages
- 934-941
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2170925735
- Cited by
- 123
- References
- 35
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 12 · 2023: 5 · 2022: 4 · 2021: 7 · 2020: 8 · 2019: 5 · 2018: 6 · 2017: 5 · 2016: 3 · 2015: 6 · 2014: 7 · 2013: 5 · 2012: 16
- FWCI
- 9.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r03mh073579-02)
- National Institute of Mental Health (MH-073579)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- antidepressant discontinuation, major depressive disorder, panic disorder, bipolar disorder, discontinuation symptoms
- MeSH terms
- Adult, Antidepressive Agents, Bipolar Disorder, Major Depressive Disorder, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Risk Factors, Substance Withdrawal Syndrome, Time Factors, Proportional Hazards Models, Survival Analysis, Panic Disorder, Treatment Outcome, Risk Assessment, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.